Mark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.
Mark J. Roschewski, MD
Articles by Mark J. Roschewski, MD
Mark J. Roschewski, MD, discusses the preliminary results of a phase 2 trial of copanlisib and rituximab as treatment of patients with untreated follicular lymphoma.